Monoclonal antibody · Antagonist of tumor necrosis factor alpha (TNF) · developed by Abbvie
ApprovedFDA, Dec 2002
1Registered trials
What is CHS-1420?
CHS-1420 is an adalimumab product, a monoclonal antibody that binds TNF-alpha and blocks its interaction with the p55 and p75 TNF receptors. It also lyses TNF-expressing cells in the presence of complement. It is studied in plaque psoriasis.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Abrilada, Amjevita, Cyltezo, Yuflyma
Drug type
Monoclonal antibody
Targets
tumor necrosis factor alpha (TNF)
Mechanism
Antagonist of tumor necrosis factor alpha (TNF)
Pathways
TNF-alpha signaling blockade of p55 and p75 TNF receptors, complement-dependent lysis of TNF-expressing cells, reduction of leukocyte migration via adhesion molecules (ELAM-1, VCAM-1, ICAM-1)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.